Behavioural effects and regulation of PKCalpha and MAPK by huprine X in middle aged mice

Pharmacol Biochem Behav. 2010 Jun;95(4):485-93. doi: 10.1016/j.pbb.2010.03.013. Epub 2010 Apr 2.

Abstract

The behavioural effects of huprine X, a new anticholinesterasic inhibitor, as well as its effects on the regulation of protein kinase C (PKC), mitogen activated protein kinase (MAPK) and alpha-secretase (ADAM10 and TACE/ADAM17) related to amyloid precursor protein (APP) processing remain to be established. In the present work, 12 month old 126/SvxC57b/6 male mice which received chronic i.p. treatment with either saline, huprine X (0.04 micromol kg(-1) or huprine X (0.12 micromol kg(-1), were submitted to a battery of behavioural tests and thereafter the brains were dissected to study the neurochemical effects induced by huprine X. The results show that, in a dose dependent manner, huprine X facilitates learning and memory in the Morris water maze and improves some indicators of emotionality without inducing adverse effects, affecting motor activity nor anxiety-like behaviours, as measured in the open-field and corner tests. Moreover activation of downstream PKC/MAPK signaling pathways may underly these behavioural effects as well as the stimulation of the non-amyloidogenic processing of APP. Results obtained herein using a sample of aged animals strongly suggest that huprine X constitutes a promising therapeutic agent for the treatment of cholinergic dysfunction underlying aging and/or dementias.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM Proteins / metabolism
  • ADAM10 Protein
  • ADAM17 Protein
  • Aging
  • Aminoquinolines / administration & dosage
  • Aminoquinolines / adverse effects
  • Aminoquinolines / pharmacology*
  • Aminoquinolines / therapeutic use
  • Amyloid Precursor Protein Secretases / metabolism
  • Amyloid beta-Protein Precursor / metabolism
  • Animals
  • Behavior, Animal / drug effects*
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / metabolism
  • Cholinesterase Inhibitors / administration & dosage
  • Cholinesterase Inhibitors / adverse effects
  • Cholinesterase Inhibitors / pharmacology*
  • Cholinesterase Inhibitors / therapeutic use
  • Dose-Response Relationship, Drug
  • Heterocyclic Compounds, 4 or More Rings / administration & dosage
  • Heterocyclic Compounds, 4 or More Rings / adverse effects
  • Heterocyclic Compounds, 4 or More Rings / pharmacology*
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Learning / drug effects
  • Male
  • Membrane Proteins / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mitogen-Activated Protein Kinases / metabolism*
  • Motor Activity / drug effects
  • Protein Kinase C-alpha / metabolism*
  • Protein Transport / drug effects
  • Random Allocation
  • Signal Transduction / drug effects
  • Time Factors

Substances

  • Aminoquinolines
  • Amyloid beta-Protein Precursor
  • Cholinesterase Inhibitors
  • Heterocyclic Compounds, 4 or More Rings
  • Membrane Proteins
  • huprine X
  • Prkca protein, mouse
  • Protein Kinase C-alpha
  • Mitogen-Activated Protein Kinases
  • Amyloid Precursor Protein Secretases
  • ADAM Proteins
  • ADAM10 Protein
  • Adam10 protein, mouse
  • ADAM17 Protein
  • Adam17 protein, mouse